Suppr
超能文献

A Golden Hour and Golden Opportunity for β-Cell Preservation.

作者信息

Evans-Molina Carmella, Oram Richard A

机构信息

Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.

Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.

出版信息

Diabetes. 2024 Jun 1;73(6):834-836. doi: 10.2337/dbi24-0019.

DOI:10.2337/dbi24-0019

PMID:38768367

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11109773/

Abstract

摘要

相似文献

A Golden Hour and Golden Opportunity for β-Cell Preservation.

Diabetes. 2024 Jun 1;73(6):834-836. doi: 10.2337/dbi24-0019.

Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.

Drugs. 2025 Apr;85(4):457-473. doi: 10.1007/s40265-025-02150-8. Epub 2025 Jan 28.

Diabetes treatments near and far.

Nat Biotechnol. 1996 Apr;14(4):428. doi: 10.1038/nbt0496-428b.

Preservation of beta cell function.

Pediatr Diabetes. 2010 May;11(3):152-3. doi: 10.1111/j.1399-5448.2010.00675.x.

FDA approves teplizumab: a milestone in type 1 diabetes.

Lancet Diabetes Endocrinol. 2023 Jan;11(1):18. doi: 10.1016/S2213-8587(22)00351-5. Epub 2022 Nov 24.

An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19.

JAMA. 2021 Mar 2;325(9):880-881. doi: 10.1001/jama.2020.24415.

The future is on the way: β cell function preservation for type 1 diabetes.

Med. 2024 Jan 12;5(1):4-6. doi: 10.1016/j.medj.2023.11.003.

Sanofi to propel inhalable insulin Afrezza into market.

Nat Biotechnol. 2014 Sep;32(9):851-2. doi: 10.1038/nbt0914-851a.

Alzheimer's drug approvals create prescribing dilemmas.

Science. 2024 Nov;386(6721):472-473. doi: 10.1126/science.adu2383. Epub 2024 Oct 31.

Anti-CD3 drug keeps diabetes at bay.

Nat Biotechnol. 2019 Oct;37(10):1099-1101. doi: 10.1038/d41587-019-00025-4.

引用本文的文献

Call for Standardization of C-Peptide Measurement.

J Diabetes Sci Technol. 2025 Aug 8:19322968251362848. doi: 10.1177/19322968251362848.

The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment-2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum.

Diabetologia. 2025 Jul 30. doi: 10.1007/s00125-025-06462-y.

A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies.

BMC Med. 2025 Jul 1;23(1):351. doi: 10.1186/s12916-025-04201-z.

Harnessing Machine Learning, a Subset of Artificial Intelligence, for Early Detection and Diagnosis of Type 1 Diabetes: A Systematic Review.

Int J Mol Sci. 2025 Apr 22;26(9):3935. doi: 10.3390/ijms26093935.

Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.

Drugs. 2025 Apr;85(4):457-473. doi: 10.1007/s40265-025-02150-8. Epub 2025 Jan 28.

本文引用的文献

Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes.

Diabetes. 2024 Jun 1;73(6):823-833. doi: 10.2337/dbi23-0012.

Prevention of cardiorenal complications in people with type 2 diabetes and obesity.

Cell Metab. 2024 Feb 6;36(2):338-353. doi: 10.1016/j.cmet.2023.12.018. Epub 2024 Jan 9.

A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes.

Nat Commun. 2023 Nov 8;14(1):7214. doi: 10.1038/s41467-023-42581-z.

C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.

Lancet Diabetes Endocrinol. 2023 Dec;11(12):915-925. doi: 10.1016/S2213-8587(23)00267-X. Epub 2023 Nov 3.

Teplizumab approval for type 1 diabetes in the USA.

Lancet Diabetes Endocrinol. 2023 Feb;11(2):76-77. doi: 10.1016/S2213-8587(22)00390-4. Epub 2023 Jan 6.

Endpoints for clinical trials in ophthalmology.

Prog Retin Eye Res. 2023 Nov;97:101160. doi: 10.1016/j.preteyeres.2022.101160. Epub 2023 Jan 2.

Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.

Lancet Diabetes Endocrinol. 2022 Oct;10(10):741-760. doi: 10.1016/S2213-8587(22)00218-2. Epub 2022 Sep 13.

Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia.

J Clin Invest. 2021 Feb 1;131(3). doi: 10.1172/JCI143011.

A quantitative measure of treatment response in recent-onset type 1 diabetes.

Endocrinol Diabetes Metab. 2020 May 14;3(3):e00143. doi: 10.1002/edm2.143. eCollection 2020 Jul.

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

A Golden Hour and Golden Opportunity for β-Cell Preservation.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译